It's supposedly getting easier for innovative drugs for rare diseases like Duchenne muscular dystrophy to reach the market. So why, asks Andy Extance, is hesitancy still proving devastating to desperate families?
Read more...
Post a CommentDefault CommentsFacebook Comments